| Vol. 12.47 – 11 December, 2020 |
| |
|
|
| Scientists developed immune-stimulating antibody conjugates comprising a TLR7/8 dual agonist conjugated to tumor-targeting antibodies. [Nature Cancer] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers generated a conditional triple-H1-knockout mouse strain and depleted H1 in hematopoietic cells. H1 depletion in T cells led to de-repression of T cell activation genes, a process that mimicked normal T cell activation. [Nature] |
|
|
|
| Investigators demonstrated that high-fat diet-induced obesity impaired CD8+ T cell function in the murine tumor microenvironment, accelerating tumor growth. [Cell] |
|
|
|
| The authors report that CRISPR–RfxCas13d could effectively discriminate circular RNAs from mRNAs by using guide RNAs targeting sequences spanning back-splicing junction sites featured in RNA circles. [Nature Methods] |
|
|
|
| Researchers showed that Ataxia Telangiectasia Mutated (ATM) inhibition could potentiate immune checkpoint blockade therapy by promoting cytoplasmic leakage of mitochondrial DNA (mtDNA) and activation of the cGAS/STING pathway. [Journal of Clinical Investigation] |
|
|
|
| Investigators demonstrated that tumor-derived UBR5, an E3 ligase overexpressed in human ovarian cancer (OC) associated with poor prognosis, was essential for OC progression principally by promoting tumor-associated macrophage recruitment and activation via key chemokines and cytokines. [Nature Communications] |
|
|
|
| Scientists showed that B7-CD28 co-stimulation and B7 expression by specific antigen-presenting cell types were required for clonal deletion and for regulatory T cell generation from endogenous tissue-restricted antigen-specific thymocytes. [Nature Communications] |
|
|
|
| To assess the relevance of autophagy to T cell allo-immunity, the authors generated T cell specific ATG5 knock-out mice. Deficiency of ATG5 dependent autophagy reduced T cell proliferation, increased apoptosis following in vitro and in vivo allo-stimulation. [Cancer Research] |
|
|
|
| The authors investigated roles of SKIL in tumorigenesis and immune escape of non-small-cell lung cancer (NSCLC). SKIL expression levels in NSCLC cell line, clinical sample, and adjacent normal tissue were measured by quantitative PCR, western blot, or immunohistochemistry. [Cell Death & Disease] |
|
|
|
| Scientists assessed the effects that menstrual blood-derived stromal cells had on the recruitment of macrophages and other innate immune cells in two mouse models of acute inflammation, a thioglycollate-elicited peritonitis model and a monobacterial sepsis model. [Scientific Reports] |
|
|
|
| Forcing NLRC5 expression promoted Vγ9Vδ2 T cell-mediated killing of tumor cells in a BTN3A-dependent manner. [iScience] |
|
|
|
| Oral administration of β-elemene, contained in various foodstuffs, downregulated expressions of inflammatory cytokines and increased Foxp3+CD4+ T cells in adipose tissue of obese mice. [iScience] |
|
|
|
|
| Scientists provide an overview of what is known about natural killer (NK) tumor infiltration and surveillance and about the mechanisms by which NK cells become dysfunctional. [Cancer Discovery] |
|
|
|
| The authors discuss natural killer cells’ cytotoxicity and modulation function in gastrointestinal cancer and the current application in clinical therapy. [Oncogene] |
|
|
|
|
| Fate Therapeutics, Inc. announced positive interim data from the company’s dose escalation Phase I study of FT516 in combination with rituximab for patients with relapsed/refractory B-cell lymphoma. [Fate Therapeutics, Inc.] |
|
|
|
| The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a Biologics License Application to the FDA seeking approval of amivantamab for the treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy. [Janssen LLC] |
|
|
|
|
| January 19 – 21, 2021 Virtual |
|
|
|
|
|
| Karolinska Institutet – Solna, Sweden |
|
|
|
| Rubius Therapeutics – Cambridge, Massachusetts, United States |
|
|
|
| Queen’s University – Kingston, Ontario, Canada |
|
|
|
| Genentech, Inc. – South San Francisco, California, United States |
|
|
|
| H. Lee Moffitt Cancer Center & Research Institute – Tampa, Florida, United States |
|
|
|
|